Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$3.16 -1.6%	$2.91	$2.46 ▼ $4.15	$270.43M	0.18	315,239 shs	340,714 shs
CNTX Context Therapeutics	$0.63 -3.6%	$0.75	$0.49 ▼ $2.75	$56.46M	1.86	301,747 shs	170,618 shs
GLUE Monte Rosa Therapeutics	$4.91 -0.2%	$4.44	$3.21 ▼ $12.40	$302.01M	1.4	1.08 million shs	380,743 shs
NGNE Neurogene	$19.76 -3.1%	$15.84	$6.88 ▼ $74.49	$281.82M	1.57	250,566 shs	112,718 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	0.00%	-0.63%	+15.33%	+0.96%	-12.47%
CNTX Context Therapeutics	0.00%	-5.23%	-11.58%	-25.20%	-67.89%
GLUE Monte Rosa Therapeutics	0.00%	-2.00%	+23.37%	-27.04%	+28.20%
NGNE Neurogene	0.00%	-9.48%	+9.84%	+17.13%	-53.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	3.3484 of 5 stars	3.3	4.0	2.7	2.5	1.3
CNTX Context Therapeutics	3.0723 of 5 stars	3.6	2.0	3.5	1.7	1.3
GLUE Monte Rosa Therapeutics	2.2864 of 5 stars	3.4	1.0	2.0	3.3	0.6
NGNE Neurogene	3.4456 of 5 stars	4.4	3.0	2.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	89.87% Upside
CNTX Context Therapeutics	3.20	Buy	$6.00	853.29% Upside
GLUE Monte Rosa Therapeutics	2.75	Moderate Buy	$15.50	215.68% Upside
NGNE Neurogene	2.71	Moderate Buy	$45.40	129.76% Upside

Current Analyst Ratings Breakdown

Latest CNTX, AVIR, NGNE, and GLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$22.00 ➝ $26.00
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
5/16/2025	NGNE Neurogene	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	NGNE Neurogene	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$38.00 ➝ $24.00
5/13/2025	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00
5/8/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/29/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/29/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/21/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/14/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$45.00 ➝ $16.00
4/11/2025	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.20 ➝ $6.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$6.65 per share	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
GLUE Monte Rosa Therapeutics	$159.49M	1.89	N/A	N/A	$3.58 per share	1.37
NGNE Neurogene	$925K	304.67	N/A	N/A	$14.51 per share	1.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$135.96M	-$1.65	N/A	N/A	N/A	N/A	-34.90%	-32.38%	8/6/2025 (Estimated)
CNTX Context Therapeutics	-$23.96M	-$0.31	N/A	N/A	N/A	N/A	-58.76%	-55.80%	8/6/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$135.35M	$0.08	N/A	N/A	N/A	N/A	-62.68%	-38.83%	8/14/2025 (Estimated)
NGNE Neurogene	-$36.32M	-$4.35	N/A	N/A	N/A	N/A	-32.81%	-27.96%	8/8/2025 (Estimated)

Latest CNTX, AVIR, NGNE, and GLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CNTX Context Therapeutics	-$0.05	-$0.05	N/A	-$0.05	N/A	N/A
5/12/2025	Q1 2025	AVIR Atea Pharmaceuticals	-$0.56	-$0.40	+$0.16	-$0.40	N/A	N/A
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million
3/24/2025	Q4 2024	NGNE Neurogene	-$1.04	-$0.99	+$0.05	-$0.99	N/A	$0.93 million
3/20/2025	Q4 2024	CNTX Context Therapeutics	-$0.05	-$0.04	+$0.01	N/A	N/A	N/A
3/20/2025	Q4 2024	GLUE Monte Rosa Therapeutics	-$0.37	$0.23	+$0.60	$0.23	$43.73 million	$14.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.33	19.33
CNTX Context Therapeutics	N/A	36.91	36.91
GLUE Monte Rosa Therapeutics	N/A	6.03	6.03
NGNE Neurogene	N/A	9.09	9.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
CNTX Context Therapeutics	14.03%
GLUE Monte Rosa Therapeutics	79.96%
NGNE Neurogene	52.37%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
CNTX Context Therapeutics	2.80%
GLUE Monte Rosa Therapeutics	6.90%
NGNE Neurogene	11.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	85.58 million	69.43 million	Optionable
CNTX Context Therapeutics	7	89.70 million	72.72 million	Not Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.44 million	Optionable
NGNE Neurogene	90	14.26 million	13.38 million	Optionable

CNTX, AVIR, NGNE, and GLUE Headlines

Recent News About These Companies

Neurogene (NGNE) Gets a Buy from BMO Capital

June 14 at 8:26 PM | theglobeandmail.com

Neurogene (NGNE) Gets a Buy from TD Cowen

June 14 at 8:26 PM | theglobeandmail.com

Neurogene price target raised to $26 from $22 at BMO Capital

June 13 at 10:56 AM | investing.com

BMO Capital Markets Issues Positive Forecast for Neurogene (NASDAQ:NGNE) Stock Price

June 13 at 3:21 AM | americanbankingnews.com

Neurogene Inc. (NASDAQ:NGNE) Given Average Rating of "Moderate Buy" by Analysts

June 13 at 1:55 AM | americanbankingnews.com

Neurogene (NASDAQ:NGNE) Given New $26.00 Price Target at BMO Capital Markets

June 12, 2025 | marketbeat.com

L’objectif de prix de Neurogene relevé à 26€ contre 22€ par BMO Capital

June 11, 2025 | fr.investing.com

Two Sigma Investments LP Invests $472,000 in Neurogene Inc. (NASDAQ:NGNE)

June 10, 2025 | marketbeat.com

Neurogene Inc. (NASDAQ:NGNE) Receives Average Rating of "Moderate Buy" from Brokerages

June 8, 2025 | marketbeat.com

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | businesswire.com

Squarepoint Ops LLC Has $398,000 Holdings in Neurogene Inc. (NASDAQ:NGNE)

June 6, 2025 | marketbeat.com

Neurogene Reports Q1 2025 Financial Progress and Updates

May 31, 2025 | tipranks.com

Stifel maintient sa recommandation d’achat sur Neurogene avec un objectif de 46€

May 29, 2025 | fr.investing.com

Deutsche Bank AG Sells 181,997 Shares of Neurogene Inc. (NASDAQ:NGNE)

May 23, 2025 | marketbeat.com

80,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Bought by Vestal Point Capital LP

May 21, 2025 | marketbeat.com

Raiffeisen Bank International AG Makes New Investment in Neurogene Inc. (NASDAQ:NGNE)

May 20, 2025 | marketbeat.com

The Manufacturers Life Insurance Company Invests $322,000 in Neurogene Inc. (NASDAQ:NGNE)

May 20, 2025 | marketbeat.com

Neurogene (NASDAQ:NGNE) Stock Rating Lowered by Baird R W

May 19, 2025 | marketbeat.com

RTW Investments LP Purchases 215,000 Shares of Neurogene Inc. (NASDAQ:NGNE)

May 18, 2025 | marketbeat.com

Baird Downgrades Neurogene (NGNE)

May 16, 2025 | msn.com

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

May 16, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX, AVIR, NGNE, and GLUE Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$3.16 -0.05 (-1.56%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.23 +0.07 (+2.22%)

As of 04:05 AM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Context Therapeutics NASDAQ:CNTX

$0.63 -0.02 (-3.56%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.62 -0.01 (-1.18%)

As of 04:12 AM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.91 -0.01 (-0.20%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$4.92 +0.00 (+0.10%)

As of 06/13/2025 05:34 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Neurogene NASDAQ:NGNE

$19.76 -0.64 (-3.14%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$19.77 +0.01 (+0.08%)

As of 06/13/2025 04:04 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time